Low-dose, long-term fumaric acid esters in recalcitrant cutaneous sarcoidosis : Report of two cases
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Fumaric acid esters lead to reduction of cell fusion and inhibition of giant cell formation in vitro, which is considered to be a reason for their therapeutic effect on cutaneous granulomatous diseases. We have reported that successful treatment of the skin lesions of a patient with recalcitrant systemic sarcoidosis with Fumaderm® (Biogen, Munich, Germany; 360-720 mg/day dimethyl fumarate) had to be discontinued due to the development of lymphocytopenia. Therefore, we treated two further patients with the low-dose Fumaderm® Initial (90 mg/day dimethyl fumarate) and observed a partial remission of the skin lesions over a minimum 18 month follow-up without signs of lymphocytopenia.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:72 |
|---|---|
| Enthalten in: |
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete - 72(2021), 10 vom: 18. Okt., Seite 909-912 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Niedrig dosierte Fumarsäureester-Langzeittherapie bei behandlungsresistenter kutaner Sarkoidose : Bericht über 2 Fälle |
|---|
| Beteiligte Personen: |
Zouboulis, Christos C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Completed 27.09.2021 Date Revised 27.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00105-021-04766-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321575911 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321575911 | ||
| 003 | DE-627 | ||
| 005 | 20231225180114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-021-04766-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1071.xml |
| 035 | |a (DE-627)NLM321575911 | ||
| 035 | |a (NLM)33598739 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Zouboulis, Christos C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Low-dose, long-term fumaric acid esters in recalcitrant cutaneous sarcoidosis |b Report of two cases |
| 246 | 3 | 3 | |a Niedrig dosierte Fumarsäureester-Langzeittherapie bei behandlungsresistenter kutaner Sarkoidose : Bericht über 2 Fälle |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2021 | ||
| 500 | |a Date Revised 27.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Fumaric acid esters lead to reduction of cell fusion and inhibition of giant cell formation in vitro, which is considered to be a reason for their therapeutic effect on cutaneous granulomatous diseases. We have reported that successful treatment of the skin lesions of a patient with recalcitrant systemic sarcoidosis with Fumaderm® (Biogen, Munich, Germany; 360-720 mg/day dimethyl fumarate) had to be discontinued due to the development of lymphocytopenia. Therefore, we treated two further patients with the low-dose Fumaderm® Initial (90 mg/day dimethyl fumarate) and observed a partial remission of the skin lesions over a minimum 18 month follow-up without signs of lymphocytopenia | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cell fusion | |
| 650 | 4 | |a Giant cell formation | |
| 650 | 4 | |a Granulomatous diseases | |
| 650 | 4 | |a Lymphocytopenia | |
| 650 | 4 | |a Side effects | |
| 650 | 7 | |a Fumarates |2 NLM | |
| 650 | 7 | |a Dimethyl Fumarate |2 NLM | |
| 650 | 7 | |a FO2303MNI2 |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete |d 1952 |g 72(2021), 10 vom: 18. Okt., Seite 909-912 |w (DE-627)NLM000041157 |x 1432-1173 |7 nnns |
| 773 | 1 | 8 | |g volume:72 |g year:2021 |g number:10 |g day:18 |g month:10 |g pages:909-912 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-021-04766-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 72 |j 2021 |e 10 |b 18 |c 10 |h 909-912 | ||